<DOC>
	<DOCNO>NCT01503749</DOCNO>
	<brief_summary>The investigator aim investigate safety efficacy peripheral blood monocyte treatment patient advance liver cirrhosis .</brief_summary>
	<brief_title>Safety Efficacy Study Peripheral Blood Mononucleated Cells Treatment Liver Cirrhosis</brief_title>
	<detailed_description>G-colony stimulating factor ( 5ug/kg/day ) administer twice subcutaneously 3 day three patient liver cirrhosis . On day 4th , plasmapheresis do collect peripheral blood mononucleated cell . And go infuse collect peripheral blood mononucleated cell portal vein patient ultrasonographic guidance .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>1 . 20 = &lt; Age &lt; 80 2 . Advanced liver cirrhosis ChildPugh score 8 9 ( include patient radiologic evidence remnant HCC 2 year treatment ) 1 . HBsAgpositive 2 . Active status hepatocellular carcinoma ( HCC ) ( except patient radiologic evidence remnant HCC 2 year treatment ) 3 . History hemochromatosis and/or autoimmune hepatitis 4 . Pregnant woman lactate woman 5 . Hemoglobin &lt; 8g/dL ( male ) , 7.5g/dL ( female ) white blood cell ( WBC ) &lt; 1,500 mm3 Neutrophils &lt; 500/mm3 platelet count &lt; 50,000/mm3 6 . Serum creatinine &gt; 1.5 x normal upper limit creatinine clearance &lt; 60 ml/min 7 . Presence sign malignant tumor tumor suspect symptom , history malignant tumor recurrence rate great 20 % within two year 8 . Gastrointestinal bleeding within last 3 month history spontaneous bacterial peritonitis 9 . Presence portal vein thrombosis 10 . Presence acute infection</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>